Goelzer S L, Farin-Rush C, Coursin D B
Department of Anesthesiology, University of Wisconsin, Madison 53792.
Crit Care Med. 1988 Jan;16(1):8-10. doi: 10.1097/00003246-198801000-00002.
Ranitidine, a furan H2 receptor antagonist, is increasingly prescribed in the ICU setting. Before the availability of parenteral ranitidine, cimetidine had been the sole H2 blocker used to decrease gastric acidity in this setting. However, cimetidine has recently been shown to transiently, but significantly, reduce mean arterial pressure due to direct vasodilation in a critically ill population. Therefore, this double-blind prospective study was designed to examine the hemodynamic effects of iv ranitidine in an ICU population. Twenty-six critically ill hemodynamically stable patients were studied; all patients were already receiving ranitidine and had an arterial line and a pulmonary artery catheter in place. This study demonstrated that an iv infusion of ranitidine did not produce clinically significant hemodynamic effects in this patient population.
雷尼替丁是一种呋喃类H2受体拮抗剂,在重症监护病房(ICU)环境中越来越多地被使用。在胃肠外雷尼替丁可用之前,西咪替丁一直是该环境中唯一用于降低胃酸度的H2阻滞剂。然而,最近研究表明,在危重症人群中,西咪替丁由于直接血管舒张作用可短暂但显著降低平均动脉压。因此,本双盲前瞻性研究旨在探讨静脉注射雷尼替丁对ICU人群的血流动力学影响。对26例血流动力学稳定的危重症患者进行了研究;所有患者均已接受雷尼替丁治疗,并已置入动脉导管和肺动脉导管。本研究表明,静脉输注雷尼替丁对该患者群体未产生具有临床意义的血流动力学影响。